eFFECTOR Therapeutics

eFFECTOR Therapeutics

  • Founded: 2012
  • Location: Solana Beach, CA
  • Employee range: 11 - 50
  • Clinical stage: Clin2b
  • Therapy area: NSCLC
  • Drug types: ONC
  • Lead product: Tomivosertib
  • Product link: https://effector.com/pipeline/
  • Funding: $7.7M stock Jun 2023; $8.7M stock May 2023; $39M C Aug 2017; $56M B Dec 2015/Feb 2016



job board

Short description:

Small Molecules

Drug notes:

Zotatifin Clin2a NSCLC; elF4Ei Clin0 solid tumors

Long description:

eFFECTOR Therapeutics is working to develop better medicines to treat cancer. Cancer is a complex and aggressive disease that is driven by genetic mutations that enable cells to evade existing therapeutics. To overcome this, eFFECTOR is pioneering a new class of drugs called selective translational regulator inhibitors (STRIs). STRIs work via various mechanisms from augmenting the efficacy of existing therapies to targeting immune suppression factors and resistance mechanisms. eFFECTOR’s lead STRI candidate, tomivosertib, is a potent and highly selective MNK inhibitor to downregulate immune suppressive responses. Tomivosertib has shown promising Phase 2a clinical trial results and is now being initiated in Phase 2b.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com